Use of sustained release dexamethasone in post-cataract surgery inflammation
View Patent ↗The present embodiments provide for a treatment regimen and use of a short-term sustained release liquid formulation of dexamethasone in citrate, wherein a single administration of a minute dosage form into the anterior chamber of the eye provides for anti-inflammatory therapy following cataract surgery.
1. A kit for the treatment of inflammation in the eye comprising:
a vial containing a formulation consisting essentially of dexamethasone and triethyl acetyl citrate, wherein the w/w ratio of the dexamethasone:triethyl acetyl citrate is selected from the group consisting of about 6:94, about 9:91, and about 12:88;
an injection syringe;
a needle;
a cannula;
a dose loading guide; and
a dose delivery guide.
2. The kit of claim 1 , wherein the dose loading guide is designed to load a dose of about 4 μL to about 6 μL.
3. The kit of claim 2 , wherein the dose loading guide is designed to load a dose of about 5 uL.
4. The kit of claim 1 , wherein the concentration of the dexamethasone is about 9% w/w and the concentration of the triethyl acetyl citrate is about 91% w/w.
5. The kit of claim 4 , wherein the dose loading guide is designed to load a dose of about 5 uL.
6. The kit of claim 1 , further comprising instructions for administration of a single unit dose of about 5 μL of the formulation into the anterior chamber of the eye following cataract surgery.
7. A unit dosage form consisting essentially of about 4 μL to about 6 μL of a composition consisting essentially of about 9% (w/w) dexamethasone and about 91% (w/w) triethyl acetyl citrate.
8. The unit dosage form of claim 7 , wherein the volume of the composition is about 5 μL.
9. The unit dosage form of claim 7 , wherein the dose of the dexamethasone in the pharmaceutical composition is about 342 μg to about 697 μg.
10. The unit dosage form of claim 7 , wherein the dose of dexamethasone in the composition is about 517 μg.
11. A unit dosage form comprising an injection syringe containing about 4 μL to about 6 μL of a composition consisting essentially of about 9% (w/w) dexamethasone and about 91% (w/w) triethyl acetyl citrate.
12. The unit dosage form of claim 11 , wherein the volume of the composition is about 5 μL.
13. The unit dosage form of claim 11 , wherein the dose of the dexamethasone in the pharmaceutical composition is about 342 μg to about 697 μg.
14. The unit dosage form of claim 11 , wherein the dose of dexamethasone in the composition is about 517 μg.